Sensorion SA (ALSEN.PA)

EUR 0.64

(-6.16%)

Market Cap (In EUR)

192.23 Million

Revenue (In EUR)

4.74 Million

Net Income (In EUR)

-22.06 Million

Avg. Volume

47.15 Thousand

Currency
EUR
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.403-1.04
PE
-
EPS
-
Beta Value
1.343
ISIN
FR0012596468
CUSIP
F8312Z102
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Ms. Nawal Ouzren
Employee Count
-
Website
https://www.sensorion.com
Ipo Date
2015-04-21
Details
Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.